Halozyme Therapeutics (HALO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations & Corporate CommunicationsHelen Torley - President and CEONicole LaBrosse - CFOSadia Rahman - Vice President, Biopharma Equity ResearchMichael Difiore - Managing DirectorAdam Ferrarini - Biotech Equity Research AssociateDavid Risinger - Senior Managing Director, Biopharma Conference Call Participants Sean Laaman - AnalystMitchell Kapoor - Director, Senior Biotechno ...

Halozyme Therapeutics (HALO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Bailey, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's First Quarter twenty twenty five Financial and Operating Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Please note this event is being recorded. I will now turn the ...

Halozyme Therapeutics, Inc. First Quarter Financial & Operating Results NASDAQ: HALO May 6, 2025 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2025 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such guidan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 _______________________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Financial Performance - Total revenue for Q1 2025 increased by 35% year-over-year to $265 million, with royalty revenue rising by 39% to $168 million[1] - Net income for Q1 2025 rose by 54% year-over-year to $118 million, while adjusted EBITDA increased by 40% to $162 million[1] - Total revenues for Q1 2025 reached $264.861 million, a 35.2% increase from $195.879 million in Q1 2024[22] - Royalty revenues increased to $168.192 million in Q1 2025, up 39.6% from $120.593 million in Q1 2024[22] - Net income for Q1 2025 was $118.095 million, representing a 53.5% increase compared to $76.823 million in Q1 2024[22] - Adjusted EBITDA for Q1 2025 was $161.983 million, compared to $115.748 million in Q1 2024, reflecting a 39.9% growth[26] - GAAP diluted earnings per share (EPS) for Q1 2025 was $0.93, up from $0.60 in Q1 2024, marking a 55% increase[28] Financial Guidance - The company raised its 2025 financial guidance for total revenue to a range of $1,200 million to $1,280 million, representing year-over-year growth of 18% to 26%[1] - Adjusted EBITDA guidance for 2025 is now set at $790 million to $840 million, indicating growth of 25% to 33% over 2024[1] - Non-GAAP diluted EPS guidance for 2025 has been increased to a range of $5.30 to $5.70, reflecting growth of 25% to 35% year-over-year[1] Share Repurchase Program - The company announced a new $250 million share repurchase program, in addition to the previous $750 million approved program[6] - The company has outlined potential share repurchases under its share repurchase program, reflecting confidence in its financial performance[18] Product Development and Growth Opportunities - Recent product launches, including Ocrevus Zunovo and Tecentriq Hybreza, are expected to contribute to future revenue growth as partners expand coverage and reimbursement[2] - The company signed its first HVAI development agreement with an ENHANZE partner, indicating ongoing collaboration and innovation in product development[3] - The company is pursuing multiple new product approvals and reimbursement milestones, creating additional growth opportunities in the near and long term[2] - The company anticipates continued growth in royalty and milestone payments driven by partner collaborations and product launches[18] - The company is focused on the development of its ENHANZE drug delivery technology, which is expected to enhance the delivery of injectable medications[18] Cash and Assets - Cash, cash equivalents, and marketable securities increased to $747.9 million as of March 31, 2025, up from $596.1 million at the end of 2024[9] - Cash and cash equivalents increased to $176.328 million as of March 31, 2025, compared to $115.850 million at the end of 2024[24] - Total assets grew to $2.197 billion as of March 31, 2025, up from $2.063 billion at the end of 2024, indicating a 6.5% increase[24]

Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY G ...

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids, aiming to improve patient experience through rapid delivery and reduced treatment burden [3] - Halozyme has impacted one million patient lives through post-marketing use of ten commercialized products across more than 100 global markets [3] Product and Technology - Halozyme has licensed its ENHANZE® technology to major pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and AbbVie, among others [3] - The company also develops and commercializes drug-device combination products using advanced auto-injector technologies, which offer advantages such as improved convenience, reliability, and patient comfort [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing product development programs with partners like Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 4:20 PM PT / 7:20 PM ET [1] - A live audio webcast of the presentation will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [2]

Core Insights - The article emphasizes the importance of long-term wealth creation through value growth investing, value investing, and dividend investing [1] - The author expresses a commitment to writing articles focused on fundamental value investing, aiming to identify great companies at fair prices [1] Group 1 - The author has over 7 years of investing experience, primarily focusing on long-term strategies [1] - The educational background of the author is in Biology, specifically molecular cell biology, which informs their analytical approach to investing [1] - The articles will be based on personal experience, research, and literature related to building long-term wealth [1] Group 2 - The author has a beneficial long position in HALO shares, indicating a personal investment interest [2] - The article reflects the author's opinions and is not influenced by compensation from any company mentioned [2] - There is no business relationship with any company whose stock is discussed in the article [2]

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient e ...

Core Insights - Halozyme Therapeutics, Inc. announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of VYVGART® 1000mg for treating chronic inflammatory demyelinating polyneuropathy (CIDP) [1][4] - VYVGART® is the first targeted IgG Fc-antibody fragment for CIDP and represents the first novel mechanism of action for CIDP treatment in over 30 years [2] - The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date [4] Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of injected drugs [5] - The company has licensed its ENHANZE® technology to major pharmaceutical companies including Roche, Takeda, and Pfizer, impacting over one million patients globally [5] - Halozyme also develops drug-device combination products aimed at enhancing patient comfort and adherence [6] Market Implications - The EC decision on the marketing authorization application is expected within approximately two months, which will apply to all 27 EU Member States and additional countries [1][4] - The approval of VYVGART® could provide a groundbreaking treatment option for patients with rare autoimmune diseases across Europe [3]